Skip to main content

Table 1 Inclusion and exclusion criteria

From: A double blind randomised control trial investigating the efficacy of platelet rich plasma versus placebo for the treatment of greater trochanteric pain syndrome (the HIPPO trial): a protocol for a randomised clinical trial

Inclusion criteria:

 Over 18 years of age

 Symptoms consistent with GTPS present for at least 6 months

 Radiological diagnosis of GTPS using MRI, or ultrasound scan if MRI contraindicated

 Failed conservative management in any other care setting

 Patient is willing and able to provide written informed consent.

Exclusion criteria:

 Lacks capacity to provide consent

 Has hip joint osteoarthritis demonstrated on a plain radiograph, requiring treatment

 Presence of confounding pathologies on the hip MRI

 Any extensive surgery or deformity of the hip demonstrated on x-ray

 Presence of systemic disorders – coagulopathy, active infection, immune system disorders, peripheral neuropathy, malignancy, unresolved fractures

 Had any surgical treatment specifically targeted at GTPS e.g. bursectomy/ilio-tibial band lengthening

 Pregnancy

 Anti-coagulant therapy e.g. warfarin, rivaroxaban, apixaban, dabigatran

 Haemaglobin < 10 g/dl or platelets < 150,000/ul

 Unable to safely stop anti-platelet/NSAID medications e.g. recent cardiac stenting

 Has lumbar-sacral spine pathology or a recent history of acute hip trauma

 Has a recent history of acute sciatica

 Is not able to attend or comply with treatment or follow up scheduling

 Participates in any other clinical trial